Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Scientific Session

Juvenile idiopathic arthritis (JIA) and pediatric joint disorders

Session: The Pediatric Great Debate: Combination Therapy vs Step-up Therapy for Juvenile Idiopoathic Arthritis

Pediatric Great Debate Introduction

Monday, November 13, 2023
12:00 PM – 12:05 PM PT
Location: Room 6A-B
On Demand In Person Livestreamed

    Moderator(s)

  • Daniel Horton, MD, MS (he/him/his)

    Rutgers Robert Wood Johnson Medical School
    New Brunswick, NJ, United States

    Disclosure(s): Childhood Arthritis and Rheumatology Research Alliance: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Salary support for serving as JIA Committee Vice Chair and Steering Committee Member (Ongoing); Danisco USA Inc.: Grant/Research Support (Terminated, December 31, 2022)

  • Daniel Lovell, MD, MPH

    Cincinnati Children's Hospital Medical Center
    Cincinnati, OH, United States

    Disclosure(s): Abbott: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); AbbVie: Consultant (Ongoing); Amgen: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Canadian Arthritis Society: Advisor or Review Panel Member (Ongoing); Celgene: Consultant (Ongoing); Forest Research: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Hoffmann-La Roche: Consultant (Ongoing); Janssen: Consultant (Ongoing); NIH-NIAMS: Advisor or Review Panel Member (Ongoing); Novartis: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing); United Bioscience Corporation: Consultant (Ongoing); Wyeth: Consultant (Ongoing)

Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic arthritis with unknown etiology. Treatment aims to achieve disease control and options for therapy include conventional synthetic (cs) and biologic (b) disease modifying antirheumatic drugs (DMARDs). It is unclear the best initial approach to JIA treatment, and variations exit in initial therapy among providers with some choosing aggressive initial therapy combining csDMARD and bDMARD versus others choosing to step up gradually with therapy if active disease persists. Two speakers will debate data and discuss benefits for early combination versus step-up treatment strategies for JIA.

Learning Objectives:

  • Discuss data for early combination therapy in JIA.
  • Discuss data for step-up therapy in JIA.
  • Debate pros and cons for early combination versus step-up therapy for JIA.

Back to Top